Drugs that contain Casimersen

1. Drug name - AMONDYS 45

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US8524880 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Apr, 2026

(3 years from now)

US10287586 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(8 years from now)

US9228187 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(8 years from now)

CN103003430A SAREPTA THERAPS INC Antisense Molecule And Method For Treating Disease.
Oct, 2016

(5 years ago)

CN105838714A SAREPTA THERAPS INC Antisense Molecule And Method For Treating Disease.
Nov, 2030

(8 years from now)

CN105838714B SAREPTA THERAPS INC Antisense Molecules And Method For Treating Disease
Nov, 2030

(8 years from now)

IN347912B SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

IN201204202P4 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2206781A9 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP1766010A1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A4 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2499249A1 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2499249A4 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2499249B1 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758783 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies Nov, 2030

(8 years from now)

US10781450 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies Nov, 2030

(8 years from now)

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production; Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.